- Home
- BSET vs IPHA Comparison
BSET vs IPHA Comparison
Compare BSET & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BSET | IPHA |
|---|---|---|
| Founded | 1902 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 160.7M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | BSET | IPHA |
|---|---|---|
| Price | $14.00 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 23.2K | 15.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.74% | N/A |
| EPS Growth | ★ 163.06 | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $456,855,000.00 | N/A |
| Revenue This Year | $4.63 | $28.31 |
| Revenue Next Year | $4.34 | N/A |
| P/E Ratio | $20.00 | ★ N/A |
| Revenue Growth | ★ 0.96 | N/A |
| 52 Week Low | $13.96 | $1.46 |
| 52 Week High | $19.75 | $2.63 |
Technical Indicators
Market Signals| Indicator | BSET | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 36.16 | 38.70 |
| Support Level | N/A | N/A |
| Resistance Level | $17.29 | $1.88 |
| Average True Range (ATR) | 0.50 | 0.08 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 26.17 | 26.47 |
Price Performance
Historical ComparisonAbout BSET Bassett Furniture Industries Incorporated
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.